Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 92

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 92
---
 no-profit 
 procurement pricing, while the upper end reflects premium pricing in private market segment.    |

These ranges are assumptions only. Nano-Mupirocin
is still in preclinical development and has not been approved by any regulatory authority. We do not yet know the final dosage, or number
of injections required per treatment course, and actual pricing will depend on multiple factors including clinical results, regulatory
approval, reimbursement, adoption, and competition.

Epidemiology and Estimated Market Opportunity for Resistant Gonorrhea Indication

According to the CDC’s 2022 STD Surveillance
Report, the U.S. reports approximately 710,000 gonorrhea cases annually, with Ceftriaxone resistance emerging in approximately 5% of
cases [7], resulting in ~91,000 Ceftriaxone-resistant infections per year.

Total Addressable Market (TAM) for Ceftriaxone-Resistant Gonorrhea

The TAM represents the entire pool of patients who suffer from the
condition, have been diagnosed, and could theoretically benefit from our therapy.

U.S. Case

| - | Annual gonorrhea cases: ~710,000 |

| - | Ceftriaxone resistance prevalence: ~5% |

| - | Resistant infections: ~91,000 cases annually |

| - | Estimated treatment cost per patient: $600 |

| - | U.S. TAM = ~$55 million per year |

Global Case

| - | Resistance rates are higher in Asia and parts of Europe. |

| - | Conservative multiplier: 4× U.S. TAM |

| - | Global TAM ≈ $220 million per year |

Thus, we estimate that $220 million represents
the maximum revenue ceiling assuming full penetration of all diagnosed resistant gonorrhea cases worldwide.

<div align='center'>58</div>

Serviceable Obtainable Market (SOM) – Ceftriaxone-Resistant Gonorrhea

The Serviceable Obtainable Market (SOM) represents
the realistic portion of the global patient pool that can be accessed and captured by our therapy, accounting for geography, regulatory
pathways, healthcare access, and competitive penetration.

Launch strategies in infectious disease markets
typically achieve 20–40% penetration in high-need segments over five years. We conservatively assume 30% global market share capture.

Patient SOM

| - | Global resistant infections: ~364,000 cases/year (based on 
 4× U.S. burden)